Caliper Life Sciences Inc announced a non-exclusive OEM agreement with Access Genetics to market Caliper’s LabChip GX microfluidic system for molecular diagnostic applications.
Access Genetics has worked for more than a decade developing and implementing solutions enabling the delivery of molecular diagnostics. As part of this agreement, Access Genetics will incorporate web-based software, materials and protocols that Access Genetics developed specifically for use with the LabChip GX and market the combined platform’s benefits to a wide community of clinicians, pathologists, and physicians. The LabChip GX system provides laboratories, offering DNA-diagnostic testing, an innovative platform for automating numerous molecular tests on a common instrument system.
"For 10 years we have awaited an instrument platform that realizes the potential of miniaturized DNA-based diagnostics," said Dr. Ron McGlennen, founder, President, and Medical Director of Access Genetics. "The LabChip GX platform is a versatile and economical solution for clinical molecular applications."
"Our partnership with Access Genetics should accelerate adoption of LabChip GX instruments in the attractive and evolving molecular diagnostic market," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "We look forward to working with Access Genetics to optimize LabChip technology for diagnostics applications."
Source: Caliper Life Sciences
